In my previous idea dated 12/21/2018, "NKTR SHORT 1-Year, Historical supports show more downside.", I pegged a bottom support at $16. (I realize it dropped slightly below that last month).
On 12/26/2018, I updated the idea to give a range for 12/31/2019, "Bullish/Bearish Outlook Dec 30th, 2019", pegging a Bearish sentiment at ~$16.32 and Bullish sentiment at ~$36.19 for 12/31/2019. (Within range)
I listen to the Earnings Calls, although, I admit, I am at a loss with most of the terminology and technology. This week's call v. last quarter's was a huge difference in the overall sentiment coming from CEO Howard Robin. In this call, Mr. Robin, along with all others on the call, had an encouraging vibe, with positive R&D updates, increased Phase developments within their pipeline, and as mentioned earlier in the week, regulatory committees picking up the review of NKTR 181 (nektar.com/pipeline/rd-pipeline/nktr-181), to be reviewed in "the next few months".
This morning I am taking a wide shot look at Nektar's history, and preparing ranges for where the stock may go from here:
Please leave a comment, idea, constructive criticism, question, or hilarious joke to help with my growth and education. I am NOT a financial advisor, CPA, or any other sort of person you should "Take to the Bank." Do your own research. God gave you a mind of your own, use it. I am an individual investor with three NKTR options (1 Sell at 75/SH, 2 Buys at $8 and $20) contracts expiring 1/17/2019 and 21 shares (17.98/AVG cost), at this time. I share my ideas on Tradingview to lockdown my own thoughts on the product and have to look back on. If my ideas help you, GREAT!! If not, oops. Happy hunting.
WTF!!! Down to 10 shares. Should've gotten out yesterday. 3 Contracts combined down 23%, expiring Friday. I did not know the advisory board was making any kind of decisions this week for the FDA on NKTR 181. With last Friday and this past Monday markup and encouraging influences, I guess it's par for Nektar to work with market manipulators. With CBD taking the place of pain and immuno-oncology drugs, I shouldn't be surprised. Maybe Nektar needs to pay some lobbyists to get past the FDA. I'm guessing their competitors paid more to keep them out. My three years looking at Nektar as a hopeful medical breakthrough company is coming to an end. Happy Hunting.
You mean you sell call at $75 and buy call at $8 and $20? $20 call is very expensive...
QUINNsNextStep
⋅
@amanda88, Yes. $20 Call Buy with a $36.15 breakeven, Down 85%. I did that in the event that NKTR 181 had their day last quarter, maybe now in the next 3-6 months. Morningstar has a fair value set at $27, so maybe I won't lose it all. I sold the $75 Sell Call November 30, 2018 when NKTR was at $40 for $320, 99% realized. With NKTR back at $20, my $8 Call Buy is up 9.5%. Not a great strategy, but as I branched out from stocks to options, I needed a stock to learn with, and I chose NKTR, having first bought shares around $12.67 in Jan. 2017. Not until I did my Dec. 2018 Tradingview idea, did I see how this spike would end up back in the $16 range. I didn't trust myself enough to sell some puts, understanding calls better than puts at the time, but definitely should have. Thank you for your comment.